MD3222G2 - Method of endometrial cancer diagnosis - Google Patents

Method of endometrial cancer diagnosis

Info

Publication number
MD3222G2
MD3222G2 MDA20060093A MD20060093A MD3222G2 MD 3222 G2 MD3222 G2 MD 3222G2 MD A20060093 A MDA20060093 A MD A20060093A MD 20060093 A MD20060093 A MD 20060093A MD 3222 G2 MD3222 G2 MD 3222G2
Authority
MD
Moldova
Prior art keywords
endometrial cancer
endometrial
diagnosis
cancer diagnosis
determining
Prior art date
Application number
MDA20060093A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD3222F1 (en
Inventor
Думитру СОФРОНИ
Лилиан ГУЦУ
Катйа ТЕННЕР
Анатол ЧЕРНЫЙ
Михаил ТОДИРАШ
Майкл БАДЕР
Original Assignee
Общественное Медико-Санитарное Учреждение Онкологический Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общественное Медико-Санитарное Учреждение Онкологический Институт filed Critical Общественное Медико-Санитарное Учреждение Онкологический Институт
Priority to MDA20060093A priority Critical patent/MD3222G2/en
Publication of MD3222F1 publication Critical patent/MD3222F1/en
Publication of MD3222G2 publication Critical patent/MD3222G2/en

Links

Abstract

The invention refers to medicine, in particular to oncology and may be used for early noninvasive diagnosis and for endometrial cancer confirmation.Summary of the invention consists in determining the tryptophanhydroxylase-1 messenger RNA concentration in the endometrial and myometrial tissues, and in the case when in the endometrial tissue the concentration is 2…100 times greater, it is established the endometrial cancer diagnosis.The result of the invention consists in the possibility of early differential diagnosis of endometrial cancer for determining the pre- and postoperative efficient method of treatment.
MDA20060093A 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis MD3222G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Publications (2)

Publication Number Publication Date
MD3222F1 MD3222F1 (en) 2007-01-31
MD3222G2 true MD3222G2 (en) 2007-08-31

Family

ID=37776647

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060093A MD3222G2 (en) 2006-03-22 2006-03-22 Method of endometrial cancer diagnosis

Country Status (1)

Country Link
MD (1) MD3222G2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3499G2 (en) * 2007-10-12 2008-09-30 Общественное Медико-Санитарное Учреждение Онкологический Институт Method of differentiated treatment of endometrial cancer
MD492Z (en) * 2011-08-17 2012-10-31 Лорена МЕДНИКОВ Method for determining the spread of intestinal type gastric cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
H, Chen G, Zhang B. Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma Zhonghua Bing Li Xue *
Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriyama M, Karino K, Endoh J, Kitao M.Clinical evaluations of the tumor marker sialyl *
Iwanari O., Miyako J., Date Y., Nakayama S., Kijima S., Moriyama M., Karino K., Endoh J., Kitao M. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease. Gynecol Obstet Invest. 1990, № 29, p. 214-218 *
Jacobs I, Bast RC: The CA125 tumour-associated antigen: a review of the literature. *
Jacobs I., Bast R. The CA125 tumour-associated antigen: a review of the literature. *
SSEA-1 antigen for clinical gynecological disease. Gynecol Obstet Invest. 1990, № 29, p. 214-218 *
Sung C., Zheng Y., Quddus M., Kang X., Zhang Z., Lauchlan S., Zheng W. P53 as a significant prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2000 Mar, № 10(2), p. 119-127 *
Sung CJ, Zheng Y, Quddus MR, Kang X, Zhang ZF, Lauchlan SC, Zheng W.p53 as a significant prognostic marker in endometrial carcinoma. Int *
Wang H., Chen G., Zhang B. Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma. Zhonghua Bing Li Xue Za Zhi. 2002, № 31(5), p. 391-395 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3499G2 (en) * 2007-10-12 2008-09-30 Общественное Медико-Санитарное Учреждение Онкологический Институт Method of differentiated treatment of endometrial cancer
MD492Z (en) * 2011-08-17 2012-10-31 Лорена МЕДНИКОВ Method for determining the spread of intestinal type gastric cancer

Also Published As

Publication number Publication date
MD3222F1 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
LUC00011I2 (en)
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
MD3222G2 (en) Method of endometrial cancer diagnosis
TW200806293A (en) Methods of treatment with CETP inhibitors
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii
WO2007110704A3 (en) Macrolide compositions as therapeutic agent
MD3244G2 (en) Method of determining the endometrial cancer aggressivity

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees